Revue de Pneumologie Clinique

2004

DOI: 10.1016/s0761-8417(04)72083-0

|View full text |Cite

|

Sign up to set email alerts

|

Alvéolite neutrophilique due à la minocycline ?

¹

,

²

,

Olivier Gronier

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion and Literature Review1

Citation Types

Supporting

0

Mentioning

1

Contrasting

0

Year Published

2009

2009

2012

2012

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

0

Mentioning

1

Contrasting

0

Order By: Relevance

“…Manual analysis of the literature search since 2003 identified 106 publications reporting ADRs observed with tetracyclines, 7–112 including several epidemiological studies. Distributions of those cases according to tetracycline and ADR type are summarized in Table 6.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature

Lebrun‐Vignes

¹

,

²

,

³

et al. 2012

British Journal of Dermatology

View full text Add to dashboard Cite

In the absence of markedly better efficacy against the various indications for tetracyclines, the minocycline benefit/risk ratio was clearly lower than that of doxycycline, and possibly those of lymecycline and metacycline. In light of these findings, minocycline should no longer be considered first-line therapy for inflammatory skin disorders, especially acne.

“…Manual analysis of the literature search since 2003 identified 106 publications reporting ADRs observed with tetracyclines, 7–112 including several epidemiological studies. Distributions of those cases according to tetracycline and ADR type are summarized in Table 6.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature

Lebrun‐Vignes

¹

,

²

,

³

et al. 2012

British Journal of Dermatology

View full text Add to dashboard Cite

In the absence of markedly better efficacy against the various indications for tetracyclines, the minocycline benefit/risk ratio was clearly lower than that of doxycycline, and possibly those of lymecycline and metacycline. In light of these findings, minocycline should no longer be considered first-line therapy for inflammatory skin disorders, especially acne.

Minocycline induced organising pneumonia resolving without recourse to corticosteroids

2009

Respiratory Medicine CME

View full text Add to dashboard Cite

No abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.